Frenova Renal Research Launches Investigator Alliance
F1RST Up offers an exclusive alliance of 200 physician investigators, in nephrology, and accelerates study startup by eliminating the administrative and contracting burdens.
Frenova Renal Research has launched F1RST Up (Frenova Rapid STart Up), an exclusive alliance with clinical research sites selected from Frenova’s investigative site network of more than 200 physician investigators, which accelerates study startup by eliminating the administrative and contracting burdens. The investigators provide care to approximately 600,000 kidney disease patients, who have cardio-renal conditions, chronic kidney disease (CKD), end stage renal disease (ESRD), cardiovascular disease, rare diseases, and infectious diseases and transplant.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
